146 related articles for article (PubMed ID: 15375569)
1. HPV16-associated tumours: therapy of surgical minimal residual disease with dendritic cell-based vaccines.
Reinis M; Indrová M; Mendoza L; Mikysková R; Bieblová J; Bubeník J; Símová J
Int J Oncol; 2004 Oct; 25(4):1165-70. PubMed ID: 15375569
[TBL] [Abstract][Full Text] [Related]
2. Treatment of minimal residual disease after surgery or chemotherapy in mice carrying HPV16-associated tumours: Cytokine and gene therapy with IL-2 and GM-CSF.
Mikysková R; Indrová M; Símová J; Jandlová T; Bieblová J; Jinoch P; Bubeník J; Vonka V
Int J Oncol; 2004 Jan; 24(1):161-7. PubMed ID: 14654953
[TBL] [Abstract][Full Text] [Related]
3. Immune escape phenotype of HPV16-associated tumours: MHC class I expression changes during progression and therapy.
Mikysková R; Bubeník J; Vonka V; Smahel M; Indrova M; Bieblová J; Símová J; Jandlová T
Int J Oncol; 2005 Feb; 26(2):521-7. PubMed ID: 15645139
[TBL] [Abstract][Full Text] [Related]
4. Chemoimmunotherapy in mice carrying HPV16-associated, MHC class I+ and class I- tumours: Effects of CBM-4A potentiated with IL-2, IL-12, GM-CSF and genetically modified tumour vaccines.
Indrová M; Bubeník J; Mikysková R; Mendoza L; Símová J; Bieblová J; Jandlová T; Jinoch P; Smahel M; Vonka V; Pajtasz-Piasecka E
Int J Oncol; 2003 Mar; 22(3):691-5. PubMed ID: 12579325
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic dendritic cell vaccination with Ag coupled to cholera toxin in combination with intratumoural CpG injection leads to complete tumour eradication in mice bearing HPV 16 expressing tumours.
Chandy AG; Nurkkala M; Josefsson A; Eriksson K
Vaccine; 2007 Aug; 25(32):6037-46. PubMed ID: 17629599
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant cytokine treatment of minimal residual disease after surgical therapy in mice carrying HPV16-associated tumours: cytolytic activity of spleen cells from tumour regressors.
Indrová M; Mikysková R; Jandlová T; Vonka V; Bubeník J; Bieblová J
Folia Biol (Praha); 2003; 49(6):217-22. PubMed ID: 14748435
[TBL] [Abstract][Full Text] [Related]
7. Interleukin 2 gene therapy of surgical minimal residual tumour disease: characterization of cytolytic effector cells from tumour progressors and regressors.
Hájková R; Indrová M; Jandlová T; Bubeník J; Reinis M
Folia Biol (Praha); 1999; 45(6):227-31. PubMed ID: 10732718
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy, IL-12 gene therapy and combined adjuvant therapy of HPV 16-associated MHC class I-proficient and -deficient tumours.
Indrová M; Bieblová J; Jandlová T; Vonka V; Pajtasz-Piasecka E; Reinis M
Int J Oncol; 2006 Jan; 28(1):253-9. PubMed ID: 16328003
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant effect of dendritic cells transduced with recombinant vaccinia virus expressing HPV16-E7 is inhibited by co-expression of IL12.
Mackova J; Kutinova L; Hainz P; Krystofova J; Sroller V; Otahal P; Gabriel P; Nemeckova S
Int J Oncol; 2004 Jun; 24(6):1581-8. PubMed ID: 15138603
[TBL] [Abstract][Full Text] [Related]
10. HPV16E7 tumor antigen modified by KDEL sequence induce specific cytotoxic T lymphocytes-dependent antitumor immunity.
Yin R; Zheng W; Hao F; Yang XC; Zhong BY; Li QJ
J Dermatol Sci; 2009 Aug; 55(2):116-22. PubMed ID: 19500947
[TBL] [Abstract][Full Text] [Related]
11. Superior therapeutic efficacy of alphavirus-mediated immunization against human papilloma virus type 16 antigens in a murine tumour model: effects of the route of immunization.
Daemen T; Riezebos-Brilman A; Regts J; Dontje B; van der Zee A; Wilschut J
Antivir Ther; 2004 Oct; 9(5):733-42. PubMed ID: 15535411
[TBL] [Abstract][Full Text] [Related]
12. DNA vaccine encoding heat shock protein 60 co-linked to HPV16 E6 and E7 tumor antigens generates more potent immunotherapeutic effects than respective E6 or E7 tumor antigens.
Huang CY; Chen CA; Lee CN; Chang MC; Su YN; Lin YC; Hsieh CY; Cheng WF
Gynecol Oncol; 2007 Dec; 107(3):404-12. PubMed ID: 17905417
[TBL] [Abstract][Full Text] [Related]
13. HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities.
Santin AD; Bellone S; Palmieri M; Ravaggi A; Romani C; Tassi R; Roman JJ; Burnett A; Pecorelli S; Cannon MJ
Gynecol Oncol; 2006 Mar; 100(3):469-78. PubMed ID: 16249018
[TBL] [Abstract][Full Text] [Related]
14. Local IFN-gamma therapy of HPV16-associated tumours.
Mikysková R; Bieblová J; Símová J; Indrová M; Jandlová T; Vonka V; Smahel M; Bubeník J; Mendoza L
Folia Biol (Praha); 2003; 49(1):26-32. PubMed ID: 12630665
[TBL] [Abstract][Full Text] [Related]
15. Tumour-inhibitory effects of dendritic cells administered at the site of HPV 16-induced neoplasms.
Mendoza L; Bubeník J; Símová J; Korb J; Bieblová J; Vonka V; Indrová M; Mikysková R; Jandlová T
Folia Biol (Praha); 2002; 48(3):114-9. PubMed ID: 12118725
[TBL] [Abstract][Full Text] [Related]
16. Combined immunization with fusion genes of mutated E7 gene of human papillomavirus type 16 did not enhance antitumor effect.
Pokorná D; Macková J; Dusková M; Rittich S; Ludvíková V; Smahel M
J Gene Med; 2005 Jun; 7(6):696-707. PubMed ID: 15712328
[TBL] [Abstract][Full Text] [Related]
17. A DNA vaccine constructed with human papillomavirus type 16 (HPV16) E7 and E6 genes induced specific immune responses.
Yan Q; Cheung YK; Cheng SC; Wang XH; Shi M; Hu MH; Yong X
Gynecol Oncol; 2007 Jan; 104(1):199-206. PubMed ID: 17049969
[TBL] [Abstract][Full Text] [Related]
18. Murine dendritic cells modified with CXCL10 gene and tumour cell lysate mediate potent antitumour immune responses in mice.
Li B; Li Q; Zhao QL; Wei XB; Zhang XH; Wu CQ; Zhong CP
Scand J Immunol; 2007 Jan; 65(1):8-13. PubMed ID: 17212761
[TBL] [Abstract][Full Text] [Related]
19. Chemically synthesized protein as tumour-specific vaccine: immunogenicity and efficacy of synthetic HPV16 E7 in the TC-1 mouse tumour model.
Welters MJ; Filippov DV; van den Eeden SJ; Franken KL; Nouta J; Valentijn AR; van der Marel GA; Overkleeft HS; Lipford G; Offringa R; Melief CJ; van Boom JH; van der Burg SH; Drijfhout JW
Vaccine; 2004 Dec; 23(3):305-11. PubMed ID: 15530672
[TBL] [Abstract][Full Text] [Related]
20. Efficient loading of dendritic cells following cryo and radiofrequency ablation in combination with immune modulation induces anti-tumour immunity.
den Brok MH; Sutmuller RP; Nierkens S; Bennink EJ; Frielink C; Toonen LW; Boerman OC; Figdor CG; Ruers TJ; Adema GJ
Br J Cancer; 2006 Oct; 95(7):896-905. PubMed ID: 16953240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
